So for the first question, our next steps are, first of all, replicating our study in independent cohorts. It would have been better if it was in clinical trials, and we’re on the way to do that. Second thing is to look at this polygenic risk of platelets in other outcomes, for example, response to therapy and recurrence. And we’re also on the way to do that...
So for the first question, our next steps are, first of all, replicating our study in independent cohorts. It would have been better if it was in clinical trials, and we’re on the way to do that. Second thing is to look at this polygenic risk of platelets in other outcomes, for example, response to therapy and recurrence. And we’re also on the way to do that. Another thing that will also make this study impactful is to actually see what’s the biology behind this polygenic risk score association with survival. Although it does make sense that platelet biology is associated with worse prognosis and survival, but we’re also interested to see if actually the biology – what’s the actual biology behind it. As for stratifying patients based on this score, probably when we’re able to replicate the score and try to see in nomograms and in composite scores with other biomarkers, how it would improve the accuracy of predicting survival and response, we would be able to use this as a potential tool in the clinic’s future, in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
